Vai alla homepage

Pagina 4 - I migliori medici per il trattamento di Cancro al seno - TOP-156 medici

Il contenuto è conforme alla Politica editoriale di Bookimed ed è revisionato da medici

Fahad Mawlood

Tarik Salman

  • Nuova
  • 32 anni di esperienza
  • Turchia, İzmir, Medicalpoint International Hospital
  • Diseases

    • Lung Cancer
    • Skin Cancers
    • Gastrointestinal Cancers
    • Genitourinary Cancers
    • Gynecological Cancers
    • Colon Cancer
    • Breast Cancer
    • Rare Cancers

    Treatment Methods

    • Individual Treatments (Comprehensive Genomic Profiling)
    • Targeted Therapies
    • Immunotherapy
    • Cancer Vaccines
    • Chemotherapy
    • Clinical Research/Experimental Medical Research

    Experience

    • 2017- 2024: Katip Çelebi University Faculty of Medicine Atatürk Education and Research Hospital Medical Oncology Clinic Associate Professor / Lecturer
    • 2022 December – 2023 March: Academic visitor Moffitt Cancer Center Cutaenous Oncology Clinic Tampa, Florida USA
    • 2013- 2017: Katip Çelebi University Faculty of Medicine Atatürk Training and Research Hospital – Medical Oncology Clinic Specialist Physician
    • 2012-2013: Izmir Education and Research Hospital, Medical Oncology Specialist Physician
    • 2012-2012: Mersin State Hospital, Medical Oncology Specialist Physician
    • 2010-2012: Dokuz Eylül University Faculty of Medicine, Department of Medical Oncology, Sub-branch Research Assistant
    • June-August 2008, December 2008 – February 2009: Memorial Sloan Kettering Cancer Center Observership programme
    • 2007-2009: Kartal Education and Research Hospital, Medical Oncology Sub-branch Research Assistant
    • 2006-2007: Siirt State Hospital, Internal Medicine, Specialist Physician
    • 2005-2006: Çukurova University Faculty of Medicine, Medical Oncology Sub-branch Research Assistant
    • 2004-2005: SSK Siirt Hospital, Internal Medicine Specialist Physician
    • 2003-2004: SSK Mardin Hospital, Internal Medicine Specialist Physician
    • 1998-2003: SSK Izmir Training and Research Hospital, 3rd Internal Medicine Clinic, Research Assistant
    • 1998-1998: SSK Izmir Training and Research Hospital Infectious Diseases Research Assistant
    • 1997-1998: Izmir Ataturk Training and Research Hospital, Anesthesiology and Reanimation Clinic, Research Assistant
    • 1995-1997: Şırnak Cizre Central Health Center
    • 1994-1995: Şırnak İdil Oyalı Village Health Center

    Professional Memberships

    • Turkish Society of Medical Oncology 2008 
    • (2018-2021 Term Board Member)
    • Izmir Oncology Group, Board Member (2014 -…)
    • Geriatric Oncology Association, Board Member (2015-…)
    • Mediterranean Oncology Association Board Member (2020 -…)
    • Turkish Biochemistry Association, Member, 2016
    • European Society of Medical Oncology, Member, 2012
    • American Society of Clinical Oncology, Member, 2008
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Ercan Ozden

  • 5 Eccellente 1 recensioni
  • 27 anni di esperienza
  • Turchia, Istanbul, VM Medical Park Pendik Hospital
  • Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

    Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

  • Mostra di più
Mastectomia
$6,500 - $8,000
Informazioni

Gul Alco

  • 5 Eccellente 3 recensioni
  • 31 anni di esperienza
  • Turchia, Istanbul, Medipol Acibadem District Hospital
  • Education

    • 1986-1989, Bursa High School, Bursa, Turkey
    • 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
    • 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
    • 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

    Experience

    • 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
    • 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
    • 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Michael Van Kampen

  • 4.5 Buono 52 recensioni
  • 37 anni di esperienza
  • Jerman, Francoforte sul Meno, Nordwest Clinic (Krankenhaus)
  • Radiotherapy specialist
CyberKnife
$9,430.93 - $16,504.13
Informazioni

Atakan Topcu

  • 5 Eccellente 3 recensioni
  • 13 anni di esperienza
  • Turchia, Istanbul, Medipol Acibadem District Hospital
  • Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

    He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

    Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Nail Paksoy

  • 4.5 Buono 2 recensioni
  • 15 anni di esperienza
  • accreditamenti:
  • Turchia, Istanbul, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Mostra di più
Chirurgia di ricostruzione mammaria
$6,000 - $6,000
Chirurgia del tumore al seno
$5,000 - $8,000
Mastectomia
$5,000 - $7,500
Informazioni

Muzaffer Al

  • 4.7 Eccellente 3 recensioni
  • 16 anni di esperienza
  • Turchia, Istanbul, Büyük Anadolu Hospitals (BAH International)
  • Education

     

    Ondokuz Mayıs University Faculty of Medicine (1991)

    KTÜ Faculty of Medicine Farabi Hospital (Specialization.1998)

    Istanbul University Çapa Faculty of Medicine (Laparoscopic Surgery Training, 2002)

    Istanbul University Çapa Faculty of Medicine (Laparoscopic Antireflux Surgery Training, 2006)

    Istanbul University Cerrahpaşa Faculty of Medicine (General Surgery Clinic Advance Laparoscopic Surgery, Laparoscopic Bariatric Surgery, Morbid Obesity and Oncological Cancer Surgery Training, 2010i)

     

     

     

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Muhammed Mustafa Atci

  • 5 Eccellente 1 recensioni
  • 15 anni di esperienza
  • Turchia, Istanbul, İstinye University Liv Hospital Topkapı
  • Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

    He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

    Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Irfan Cicin

  • 5 Eccellente 1 recensioni
  • 29 anni di esperienza
  • Turchia, Istanbul, İstinye University Liv Hospital Topkapı
  • Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

    Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

    Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Volkan Kinas

  • 4.7 Eccellente 3 recensioni
  • 11 anni di esperienza
  • Turchia, Istanbul, Büyük Anadolu Hospitals (BAH International)
  • Specializations

     

    Cancer Surgery

    Pancreatic Surgery

    Bile Duct Surgery

    Bariatric Metabolic Surgery

    Oncological Surgery

    Breast Surgery

    Gastric cancer

    Colon cancer

    Thyroid Cancer

    Obesity Surgery

    Diabetes Surgeries

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Cagatay Arslan

  • Nuova
  • 19 anni di esperienza
  • Turchia, İzmir, Medicalpoint International Hospital
  • Education and Expertise

    • ANKARA UNIVERSITY FACULTY OF MEDICINE

    Diseases

    • Brain Tumors
    • Gastrointestinal Cancers
    • Genitourinary Cancers
    • Lymphoma
    • Malign Melanoma
    • Breast Cancer
    • Sarcomas

    Experience

    • Internal Medicine Specialist; Süleyman Demirel University Medical Faculty Hospital Internal Medicine Department
    • Medical Oncology Specialist; Hacettepe University Faculty of Medicine Oncology Hospital, Department of Medical Oncology

    Professional Memberships

    • ESMO (European Society for Medical Oncology), full membership
    • Turkish Medical Oncology Association, full membership
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Seyda Gunduz

  • 4.4 Buono 17 recensioni
  • 16 anni di esperienza
  • Turchia, Istanbul, Istinye University Liv Hospital Bahcesehir
Visita dal medico
Prezzo su richiesta
Informazioni

Sherko Kuemmel

  • Nuova
  • 29 anni di esperienza
  • Cipro, Repubblica di Cipro, German Medical Institute (GMI)
  •  Posts and Affiliations

    Clinical Director – Multidisciplinary Breast Unit Kliniken Essen-Mitte, Germany

    Lead Breast Cancer Research Program, Kliniken Essen-Mitte

    Executive Board Member of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie)

     Additional Roles

    ESMO Faculty – Breast Cancer

    Member of AWO Gyn – Commission for plastic and reconstructive surgery

    Speaker of the AGIMed – Commission for Integrative Medicine of the AGO

    Member of the Organ Commission Mamma of the AGO

    Scientific Director of the WSG study group

    Global PI, Head of clinical investigations and trials 27

    IDMC´s, Steering Boards national and international

    Scientific committee of international and national symposia in breast cancer and surgical oncology

     Organization Memberships

    Memberships: European Society of Medical Oncology, American Society of Clinical Oncology,

    European Academy of Senology, German Cancer Society, German Society of Gynecology and

    Obstetrics, Working Group for Gynecological Oncology, German Society of Senology,

     Publications

    Peer reviewed Publications: 322

    First/Senior Author: 38

    h-Index/i10-Index 66/232

    Congress Abstracts/Proceedings: 443

    Books/Book Chapter: 59

    Invited oral Presentations/Lectures: 1032

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

joseba Rebollo Liceaga

  • 4.1 Buono 3 recensioni
  • 36 anni di esperienza
  • Spanyol, Alicante, Quironsalud Torrevieja
  • Dr. Joseba Rebollo Liceaga is a seasoned medical oncologist with a comprehensive background in oncology.​

    Education and Training:

    Graduated in Medicine and Surgery from the University of Navarra (1985).​

    Completed residency in Oncology in 1987.​

    Specialist in Medical Oncology at the Clínica Universidad de Navarra (1991).​

    Professional Experience:

    Head of the Oncology Department at Clínica San Miguel de Navarra (1991–2004).​

    Associate Physician at the University Clinic of the Faculty of Medicine, University of Navarra (1995–2002).​

    Adjunct Physician at the Oncology Platform, Hospital Quirónsalud Torrevieja (2004–2014).

    Head of the Oncology Department at Hospital General de Villalba (2014–2019).​

    Currently practices as a Medical Oncology Specialist at Quirónsalud Alicante.​

    Certifications and Training:

    Completed multiple accredited courses in Multidisciplinary Oncology between 2003 and 2006.​

    Research and Publications:

    Authored research on electrochemotherapy and multidisciplinary treatment approaches in oncology.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Luna Kaduri

  • 4.4 Buono 12 recensioni
  • 31 anni di esperienza
  • Israele, Gerusalemme, Hadassah Medical Center
  • RESEARCH ACTIVITY

    1998–2000 — Conducted research on the genesis of cancer at The Royal Marsden Hospital (England).

    PUBLICATIONS

    Authored numerous peer-reviewed articles in scientific journals. Selected topics include:

    Oncotype Dx Recurrence Score in BRCA1/2 germline mutation carriers with hormone receptor-positive breast cancer.

    TP53 missense mutation recurrence in cancer patients of Arab descent.

    Adjuvant autologous vaccine for stage III microscopic melanoma: biomarker survival and enhanced response to CTLA-4 blockade.

    Prognostic significance of (R)CA15-3 assay in primary breast cancer.

    Diagnostic and prognostic value of comparative thymidine kinase 1 (TK1) activity assays in breast cancer patient serum.

    Complete remission in a BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma treated with cisplatin.

    Autologous vaccine-induced antitumor and self-reactive immune responses in melanoma: impact on patient survival and dependence on MHC class II expression.

    PROFESSIONAL AFFILIATIONS

    Israeli Society of Clinical Oncology

    Israel Medical Association

    AWARDS & GRANTS

    Cancer Genetics Research Foundation Award

    Landau Prize

    Judith Segal Memorial Award

  • Mostra di più
Informazioni

Baha Zengel

  • Nuova
  • 12 anni di esperienza
  • Turchia, İzmir, Medicalpoint International Hospital
  • Dr. Baha Zengel is a general surgeon with expertise in breast, gallbladder, thyroid diseases, and hernia repairs. He graduated from Ege University Faculty of Medicine in 1990. In 2004, he earned a doctorate in Basic Oncology from Dokuz Eylül University. He became an Associate Professor of General Surgery in 2014 through the Inter-University Board.

    Dr. Zengel is skilled in advanced surgical procedures. His experience includes skin and breast-conserving mastectomy, oncoplastic breast surgery, laparoscopic cholecystectomy, sentinel lymph node biopsy, and ROLL/SNOLL techniques. He has held important positions at Izmir Bozyaka Training and Research Hospital, including Education Officer.

    He is a member of several professional associations. He serves on the Board of Directors of the Aegean Region Surgery Association and is a founding board member of the Basic Oncology Association.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Leng Yin

  • 4.6 Eccellente 17 recensioni
  • Cina, Guangzhou, Fuda Cancer Hospital
  • Dr. Leng Yin is an experienced oncologist, specializing in liver, gallbladder, stomach, pancreas, intestinal tracts and breast treatments. She has worked in Fuda Hospital, Bumrungrad International Hospital and Royal Siriraj Hospital and is a member of The Chinese Anti-Cancer Association.

  • Mostra di più
Informazioni

Inta Jaunalksne

  • 5 Eccellente 2 recensioni
  • 49 anni di esperienza
  • Lettonia, The medical term "Jūrmala" does not appear to be a medical term and is instead the name of a city in Latvia. In this context and following your instructions to use official medical terminology as found in Indonesian literature, it would not have a translation into Italian or Indonesian because city names are typically not translated into other languages using medical terminology. It remains "Jūrmala" in both Italian and Indonesian contexts., Pallas Clinic
  • Dr. Inta Jaunalksne is an experienced immunologist with more than 30 years in the field. She specializes in virotherapy. She graduated from Riga Medical Institute and completed an internship in Internal Medicine. Dr. Jaunalksne is recognized as an expert in immunology.

    She leads the Clinical Immunology Center at Pauls Stradins Clinical University Hospital. Dr. Jaunalksne has played a key role in advancing virotherapy and immunological research. Her work has improved treatment results and introduced new therapies. She is well respected in clinical immunology.

  • Mostra di più
Informazioni